^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Published date:
02/06/2023
Excerpt:
SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid tumours harbouring oncogenic HER2 somatic mutations (ClinicalTrials.gov: NCT01953926)....Neratinib was well tolerated and showed antitumour activity in patients with metastatic gallbladder cancer or cholangiocarcinoma harbouring HER2 mutations.
DOI:
https://doi.org/10.1038/s41467-023-36399-y
Trial ID: